HC Wainwright Has Optimistic Outlook of PRLD Q2 Earnings

Prelude Therapeutics Incorporated (NASDAQ:PRLD) – Investment analysts at HC Wainwright raised their Q2 2026 earnings per share estimates for shares of Prelude Therapeutics in a research note issued on Wednesday, July 15th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.17) per share for the quarter, up from their prior estimate of ($0.23). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Prelude Therapeutics’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Prelude Therapeutics’ Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.16) EPS and FY2026 earnings at ($0.62) EPS.

A number of other research analysts have also commented on PRLD. Zacks Research raised Prelude Therapeutics to a “hold” rating in a report on Tuesday, April 28th. Weiss Ratings raised Prelude Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. Finally, D. Boral Capital assumed coverage on shares of Prelude Therapeutics in a research report on Monday, May 4th. They issued a “buy” rating and a $9.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $7.67.

Prelude Therapeutics Trading Up 0.5%

Shares of NASDAQ PRLD opened at $4.20 on Friday. Prelude Therapeutics has a 12-month low of $0.75 and a 12-month high of $5.69. The company has a market cap of $334.49 million, a PE ratio of -4.20 and a beta of 0.95. The stock has a 50 day simple moving average of $4.38 and a 200-day simple moving average of $3.56.

Prelude Therapeutics (NASDAQ:PRLD) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.14. The company had revenue of $4.58 million for the quarter, compared to analyst estimates of $4.58 million.

Institutional Investors Weigh In On Prelude Therapeutics

Large investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC increased its stake in Prelude Therapeutics by 170.7% during the first quarter. AQR Capital Management LLC now owns 33,823 shares of the company’s stock valued at $26,000 after acquiring an additional 21,330 shares during the period. Marshall Wace LLP bought a new stake in shares of Prelude Therapeutics in the 2nd quarter valued at approximately $34,000. XTX Topco Ltd grew its stake in shares of Prelude Therapeutics by 72.4% in the 2nd quarter. XTX Topco Ltd now owns 42,573 shares of the company’s stock valued at $34,000 after purchasing an additional 17,873 shares during the period. Shay Capital LLC acquired a new position in shares of Prelude Therapeutics in the 2nd quarter worth approximately $61,000. Finally, Jane Street Group LLC acquired a new position in shares of Prelude Therapeutics in the 2nd quarter worth approximately $74,000. Institutional investors own 79.72% of the company’s stock.

Insiders Place Their Bets

In other Prelude Therapeutics news, Director Orbimed Advisors Llc bought 2,815,315 shares of the stock in a transaction on Tuesday, April 21st. The shares were bought at an average price of $4.44 per share, with a total value of $12,499,998.60. Following the purchase, the director directly owned 11,808,945 shares in the company, valued at $52,431,715.80. The trade was a 31.30% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director David P. Bonita acquired 2,815,315 shares of the stock in a transaction that occurred on Tuesday, April 21st. The shares were bought at an average cost of $4.44 per share, for a total transaction of $12,499,998.60. Following the completion of the transaction, the director directly owned 11,808,945 shares of the company’s stock, valued at $52,431,715.80. This represents a 31.30% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 49.20% of the company’s stock.

About Prelude Therapeutics

Prelude Therapeutics Incorporated is a clinical-stage precision medicine company focused on the discovery and development of small molecule therapies for genetically defined oncology targets. By leveraging a chemical biology approach, the company aims to deliver targeted treatments that address key drivers of cancer cell growth and survival. Prelude’s pipeline emphasizes novel inhibitors designed to engage molecular pathways validated by both preclinical and clinical evidence.

Among Prelude’s lead programs is PRT2527, a selective PI3K‐alpha/delta inhibitor in Phase 1 clinical trials for solid tumors harboring PIK3CA and other pathway mutations.